NasdaqGS:ALNYBiotechs
Alnylam Pharmaceuticals (ALNY) Could Be 38% Undervalued After Mivelsiran Trial Progress
Alnylam Pharmaceuticals (ALNY) is in focus after presenting new mivelsiran data and trial updates at the Alzheimer’s Association International Conference, spotlighting its RNAi approach across multiple Alzheimer’s and cerebral amyloid angiopathy programs.
See our latest analysis for Alnylam Pharmaceuticals.
These Alzheimer’s and cerebral amyloid angiopathy updates land at a time when Alnylam Pharmaceuticals’ 1-year total shareholder return has declined 17.35%, while the 3-year and 5-year...